CADTH Canadian drug expert committee recommendation: Vortioxetine (Trintellix --Lundbeck Canada Inc.) indication: for the treatment of major depressive disorder in adults
The CADTH Canadian Drug Expert Committee recommends that vortioxetine be reimbursed for the treatment of major depressive disorder in adults if the following conditions are met. Conditions for Reimbursement: 1. Reimburse in a similar manner to other antidepressants for the treatment of patients with...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, February 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee recommends that vortioxetine be reimbursed for the treatment of major depressive disorder in adults if the following conditions are met. Conditions for Reimbursement: 1. Reimburse in a similar manner to other antidepressants for the treatment of patients with major depressive disorder. 2. The drug plan cost of treatment with vortioxetine should not exceed the drug plan cost of the least costly antidepressant currently reimbursed |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (9 pages) |